悪性黒色腫(メラノーマ)治療薬の世界市場及びパイプライン分析

◆英語タイトル:Global Malignant Melanoma Drug Market & Clinical Pipeline Insight
◆商品コード:KUIK60806
◆発行会社(調査会社):KuicK Research
◆発行日:2016年5月
◆ページ数:500
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥273,600見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥547,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Investigators are trying to develop innovative therapeutics for the treatment of malignant melanoma with high safety and efficacy. Surgery has remained the corner stone of cancer treatment including malignant melanoma. Cancerous region and adjoining tissue is removed to prevent it growth. Radiation therapy is also found to be effective in melanoma treatment but it causes long-tern deleterious effects on body. Chemotherapeutics can prevent malignant cancer but it side effects decrease quality of life and increase morbidity. It has been found that cancerous cells develop changes to evade the effect of the therapeutics leading to less efficacy. These facts are required to be overcome in near future and investigators are trying to develop different modalities. Some progress has been made which is expected to increase the market size of malignant melanoma.
Research and development of malignant melanoma therapeutics has gained lots of attention in past few decades due to rapidly increasing incidences. Large numbers of clinical trials have been instigated to find an effective therapeutics having high safety and efficacy levels. Various products are at different stages of clinical trials which would be introduced in coming years. Their safety and efficacy is prime concern because investigators are still trying to understand exact mechanism behind factors leading to the development of malignant melanoma. For instance, signaling pathways are complex and intertwined making it difficult for investigators to rely on single approach to treat malignant melanoma. In coming years, it is expected that investigators would be able to identify these factors resulting in development of pharmacologically superior products offering higher safety and efficacy profiles.

Malignant melanoma cells have been found to have changes in genes due to which they spread across the body. It has been found that genes like BRAF are mutated in certain individuals. By blocking their activity it would be possible to prevent the development of malignant melanoma. Side-by-side, identification of aberration in such genes will allow the investigators to identify individuals with high possibility of its development. Physicians would be able to device effective therapeutic strategies to offer better medical care. Several drug target candidates have yet to be discovered and checked for their efficacy against activity of such genes. Blocking of gene activity is difficult as their expression levels keep on changing depending upon physiological activities. Most of the studies are at incipient stages which are expected to take some time in commercialization.

Many innovative therapeutics are at various phases of clinical trials for malignant melanoma treatment. They are expected to generated statistically significant data encouraging pharmaceutical companies to proceed with higher levels of confidence. The long-term effect of these innovative therapeutics is under investigation, sufficiently high safety and efficacy data will make it easy to apply for marketing approval in different countries. In few years, owing to rapidly developing clinical pipelines, innovative malignant melanoma therapeutics are expected to enter in global market leading to increase in their market size. Future commercial success of these novel products seems to be optimistic but their commercialization may take some years.

“Global Malignant Melanoma Drug Market & Clinical Pipeline Insight” Report Highlight:
• Global Malignant Melanoma Market Analysis
• Malignant Melanoma Drug Mechanism of Action
• Global Malignant Melanoma Clinical Pipeline By Company & Phase
• Global Malignant Melanoma Clinical Pipeline: 201 Drugs
• Majority Malignant Melanoma Drugs in Preclinical Phase: 63 Drugs
• Global Malignant Melanoma Marketed Drugs Clinical Insight
• Marketed Malignant Melanoma Drugs: 25 Drugs

【レポートの目次】

1. Introduction to Malignant Melanoma

2. Malignant Melanoma Drug Mechanism of Action

3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview

4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Malignant Melanoma Drug Market Future Prospects

6. Global Malignant Melanoma Clinical Pipeline By Company & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Registered

7. Global Malignant Melanoma Marketed Drugs Clinical Insight
7.1 Talimogene Laherparepvec (IMLYGIC)
7.2 Nivolumab (Opdivo)
7.3 Temozolomide (Temodal & Temodar)
7.4 Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegintron,
Pegtron & ViraferonPeg )
7.5 Pembrolizumab (Keytruda )
7.6 Vemurafenib
7.7 Ipilimumab (Yervoy)
7.8 Cobimetinib (Cotellic)
7.9 Trametinib (Mekinist)
7.10 Tc 99m Tilmanocept (Lymphoseek)
7.11 Dabrafenib (Tafinlar)
7.12 Aldesleukin (Chiron IL-2 & Proleukin)
7.13 Interferon alpha-2b (Intron A, Viraferon & Virtron)
7.14 Interferon-beta-1b – Toray/Daiichi Sankyo (Feron)
7.15 Melanoma Vaccine – AVAX Technologies (MVax)
7.16 Interferon alpha – Swedish Orphan Biovitrim (Multiferon)
7.17 Interferon alpha-2b – Beijing Kawin Technology
7.18 Virulizin (Virulizin)
7.19 Vemurafenib Companion Diagnostic – Roche/Plexxikon (cobas 4800 BRAF V600
Mutation Test)
7.20 Dabrafenib-Trametinib Companion Diagnostic – bioMerieux/ GlaxoSmithKline/
Response Genetics (THxID-BRAF)
7.21 Interferon alpha-2b Biosimilar – Reliance Life Sciences (ReliFeron)
7.22 Technetium Tc 99m Sulfur Colloid Injection – Pharmalucence
7.23 Interferon alpha-2a (Roferon-A)
7.24 Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)
7.25 Melanoma Vaccine – GlaxoSmithKline (Melacine)

8. Competitve Landscape
8.1 AB Science
8.2 Celgene Corporation (Abraxis BioScience)
8.3 Array BioPharma
8.4 AVAX Technologies
8.5 Biogen Idec
8.6 BioVex
8.7 Bristol-Myers Squibb
8.8 Enzon Pharmaceuticals
8.9 Eisai Co
8.10 Exelixis
8.11 GlaxoSmithKline
8.12 Lorus Therapeutics (Aptose Bioscience)
8.13 Medarex
8.14 Merck
8.15 Navidea Biopharmaceuticals
8.16 Novartis
8.17 Ono Pharmaceutical
8.18 Onyx Pharmaceuticals
8.19 Pfizer
8.20 Pharmalucence (Sun Pharmaceutical Industries Limited)
8.21 Plexxikon
8.22 QIAGEN
8.23 Roche
8.24 Reliance Life Sciences
8.25 Servier
8.26 TC BioPharm
8.27 Viragen

Figure 1-1: Causes behind Development of Skin Cancer
Figure 1-2: Different Melanomas on the basis of Histology
Figure 2-1: Mechanism of Dacarbazine
Figure 2-2: Mechanism of Vemurafenib
Figure 2-3: Mechanism of Ipilimumab
Figure 2-4: Mechanism of Nivolumab
Figure 3-1: Global Malignant Melanoma Drug Market (US$ Billion), 2015-2020
Figure 3-2: Global Malignant Melanoma Drug Pipeline by Phase (%), 2016
Figure 3-3: Global Malignant Melanoma Drug Pipeline by Phase (Numbers), 2016
Figure 4-1: Malignant Melanoma Drug Market Favorable Features
Figure 4-2: Malignant Melanoma Drug Market Commercialization Challenges
Figure 8-1: AB Science Clinical Pipeline
Figure 8-2: Malignant Melanoma Clinical Pipeline
Figure 8-3: Aptose Biosciences Pipeline
Figure 8-4: Merck Clinical Pipeline
Figure 8-5: Novartis Clinical Pipeline
Figure 8-6: Plexxikon Clinical Pipeline
Figure 8-7: Roche Clinical Pipeline


【レポートのキーワード】

悪性黒色腫、メラノーマ治療薬

★調査レポート[悪性黒色腫(メラノーマ)治療薬の世界市場及びパイプライン分析]販売に関する免責事項
★調査レポート[悪性黒色腫(メラノーマ)治療薬の世界市場及びパイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆